Indanone and tetralone-ketone or hydroxyoxime as cancer therapeutic agent
Certain embodiments relate to compounds that are ER ligands, pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, in particular to such compounds that are ER [beta]-selective and/or ER [beta]-specific ligands. 某些实施方案涉及作为ER配体的化合物、其药学上可接受的盐、立体异构体及前药，特别是涉及作为ERβ选择性和/或ERβ特异性配体的此类化合物。...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | TIDWELL MICHAEL W VADLAMUDI RATNA K MCHATTIE, STANTON ANDREW J. BRENNER |
| description | Certain embodiments relate to compounds that are ER ligands, pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, in particular to such compounds that are ER [beta]-selective and/or ER [beta]-specific ligands.
某些实施方案涉及作为ER配体的化合物、其药学上可接受的盐、立体异构体及前药，特别是涉及作为ERβ选择性和/或ERβ特异性配体的此类化合物。 |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN117642375A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN117642375A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN117642375A3</originalsourceid><addsrcrecordid>eNrjZPD0zEtJzMvPS1VIzEtRKEktKUrMAfJ0s1NLQIL5RQoZlSlF-RWV-RWZuUBFxQrJiXnJqUUKJRmpRYkFqaUlmckKiempeSU8DKxpiTnFqbxQmptB0c01xNlDN7UgPz61uCAxOTUvtSTe2c_Q0NzMxMjY3NTRmBg1ABNCNR8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Indanone and tetralone-ketone or hydroxyoxime as cancer therapeutic agent</title><source>esp@cenet</source><creator>TIDWELL MICHAEL W ; VADLAMUDI RATNA K ; MCHATTIE, STANTON ; ANDREW J. BRENNER</creator><creatorcontrib>TIDWELL MICHAEL W ; VADLAMUDI RATNA K ; MCHATTIE, STANTON ; ANDREW J. BRENNER</creatorcontrib><description>Certain embodiments relate to compounds that are ER ligands, pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, in particular to such compounds that are ER [beta]-selective and/or ER [beta]-specific ligands.
某些实施方案涉及作为ER配体的化合物、其药学上可接受的盐、立体异构体及前药，特别是涉及作为ERβ选择性和/或ERβ特异性配体的此类化合物。</description><language>chi ; eng</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC USE OF COSMETICS OR SIMILAR TOILETPREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240301&DB=EPODOC&CC=CN&NR=117642375A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240301&DB=EPODOC&CC=CN&NR=117642375A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TIDWELL MICHAEL W</creatorcontrib><creatorcontrib>VADLAMUDI RATNA K</creatorcontrib><creatorcontrib>MCHATTIE, STANTON</creatorcontrib><creatorcontrib>ANDREW J. BRENNER</creatorcontrib><title>Indanone and tetralone-ketone or hydroxyoxime as cancer therapeutic agent</title><description>Certain embodiments relate to compounds that are ER ligands, pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, in particular to such compounds that are ER [beta]-selective and/or ER [beta]-specific ligands.
某些实施方案涉及作为ER配体的化合物、其药学上可接受的盐、立体异构体及前药，特别是涉及作为ERβ选择性和/或ERβ特异性配体的此类化合物。</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC USE OF COSMETICS OR SIMILAR TOILETPREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZPD0zEtJzMvPS1VIzEtRKEktKUrMAfJ0s1NLQIL5RQoZlSlF-RWV-RWZuUBFxQrJiXnJqUUKJRmpRYkFqaUlmckKiempeSU8DKxpiTnFqbxQmptB0c01xNlDN7UgPz61uCAxOTUvtSTe2c_Q0NzMxMjY3NTRmBg1ABNCNR8</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>TIDWELL MICHAEL W</creator><creator>VADLAMUDI RATNA K</creator><creator>MCHATTIE, STANTON</creator><creator>ANDREW J. BRENNER</creator><scope>EVB</scope></search><sort><creationdate>20240301</creationdate><title>Indanone and tetralone-ketone or hydroxyoxime as cancer therapeutic agent</title><author>TIDWELL MICHAEL W ; VADLAMUDI RATNA K ; MCHATTIE, STANTON ; ANDREW J. BRENNER</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN117642375A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2024</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC USE OF COSMETICS OR SIMILAR TOILETPREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>TIDWELL MICHAEL W</creatorcontrib><creatorcontrib>VADLAMUDI RATNA K</creatorcontrib><creatorcontrib>MCHATTIE, STANTON</creatorcontrib><creatorcontrib>ANDREW J. BRENNER</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TIDWELL MICHAEL W</au><au>VADLAMUDI RATNA K</au><au>MCHATTIE, STANTON</au><au>ANDREW J. BRENNER</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Indanone and tetralone-ketone or hydroxyoxime as cancer therapeutic agent</title><date>2024-03-01</date><risdate>2024</risdate><abstract>Certain embodiments relate to compounds that are ER ligands, pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, in particular to such compounds that are ER [beta]-selective and/or ER [beta]-specific ligands.
某些实施方案涉及作为ER配体的化合物、其药学上可接受的盐、立体异构体及前药，特别是涉及作为ERβ选择性和/或ERβ特异性配体的此类化合物。</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN117642375A |
| source | esp@cenet |
| subjects | ACYCLIC OR CARBOCYCLIC COMPOUNDS CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC USE OF COSMETICS OR SIMILAR TOILETPREPARATIONS |
| title | Indanone and tetralone-ketone or hydroxyoxime as cancer therapeutic agent |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A07%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TIDWELL%20MICHAEL%20W&rft.date=2024-03-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN117642375A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |